Regulatory Aspects in Gene Therapy
Author:
Cohen-Haguenauer Odile
Reference75 articles.
1. Cavazzana-Calvo M, Hacein-Bey S, de Saint-Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Le Deist F, Fischer A. Gene therapy of human severe combined immunodeficiency (SCID)-Xl disease. Science, 2000; 288: 669-672. 2. Cohen B. Trials and tribulations. Nature Genetics 2000; 24: 201. 3. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, Hawkins L, Kirn D: An adenovirus ElA mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med
6:1134-9,2000. 4. Kay MA, Manno. CS., Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, J Tai S, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, High KA: Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 2000; 24: 257-261. 5. Ylä-Herttuala S, Martin JF. Cardio-vascular gene therapy. Lancet, 2000; 355: 213-22.
|
|